The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. - Wikidata - wikimedia - TriplyDB

The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.

The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.

http://www.wikidata.org/entity/Q34310749

about

Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis Interleukin-6 blockade in ocular inflammatory diseases Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis Systemic sclerosis: current concepts in pathogenesis and therapeutic aspects of dermatological manifestations.Emerging targets for the treatment of scleroderma.Antifibrotic effects of roscovitine in normal and scleroderma fibroblasts.Hypomethylation and overexpression of ITGAL (CD11a) in CD4(+) T cells in systemic sclerosis.Serum amyloid A is a marker for pulmonary involvement in systemic sclerosis.Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.Tocilizumab for the treatment of steroid refractory graft-versus-host disease.Racial differences between blacks and whites with systemic sclerosis Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives Interleukin-6 receptor blockade suppresses subretinal fibrosis in a mouse model.Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases.Regulatory T cells and IL-17-producing cells in graft-versus-host disease.Immunotherapeutic implication of IL-6 blockade.Scleroderma therapy: clinical overview of current trends and future perspective.Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases.Targeting interleukin-6 in rheumatoid arthritis.Targeted therapies for systemic sclerosis.Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases.Animal models of scleroderma: current state and recent development.Novel investigational agents for the treatment of scleroderma.Inhibition of the interleukin-6 signaling pathway: a strategy to induce immune tolerance.IL-6 biology: implications for clinical targeting in rheumatic disease.Interleukin-6: a new therapeutic target in systemic sclerosis?A new alternative therapy in dermatology: tocilizumab.The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis.The continuing evolution of targeted therapy for inflammatory skin disease.Strategy for treatment of fibrosis in systemic sclerosis: Present and future.Interstitial lung disease in systemic sclerosis: current and future treatment.A case of rheumatoid arthritis and limited systemic sclerosis overlap successfully treated with tocilizumab for arthritis and concomitant generalized lymphadenopathy and primary biliary cirrhosis.An update on biomarker discovery and use in systemic sclerosis.Mechanistic insight into the norepinephrine-induced fibrosis in systemic sclerosis.A vitamin D analog inhibits Th2 cytokine- and TGFβ -induced periostin production in fibroblasts: a potential role for vitamin D in skin sclerosis.IFN-γ and TNF-α induce a different modulation of interleukin-6 in systemic sclerosis fibroblasts compared to healthy controls.Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis.Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).[Established medications : new areas of application].

P2860

Q26773161-48CF6869-1F49-44D1-98E2-01519C22A991 Q27011357-9826F99D-687E-4729-AD95-F1C47F2EE836 Q28073706-1747D1B9-753B-48C7-8B78-F75D87FD9D47 Q31125829-8167CE53-905A-46DF-B355-C7D1AC65B13C Q34270856-0F6B6AFE-B60A-4DC4-8AFA-C36E14A41DAA Q34489708-2792E6A0-67A1-41F9-8E91-743F5D4FEE44 Q34544210-E6B4FDBE-7167-4947-AF64-74ED94B86F50 Q35064030-4149C7A8-B6EF-4FD8-A4B4-3FEAD08DC8AE Q35724900-1C13AEB0-5C46-4617-8703-24BB5D025788 Q36677277-B82896BD-C59F-45D0-815B-93AA415C5D44 Q37026278-24C20E71-8406-406F-B451-5DA9B12949D0 Q37129649-84081610-2FC6-4AAE-910C-2A62B743AC73 Q37381549-A050494B-7463-4A72-9AFA-D1BA98BE2324 Q37729402-E84B044F-E9C9-4717-9F04-5BEE8E91200D Q37854935-FE8CE9A2-151C-414E-82FD-388F1E18310D Q37900645-B2D84A50-0733-4785-A267-E852CB45B4A2 Q37965754-94C49FCF-C5B4-4B6A-8B62-A3E90C8BF6E0 Q38046467-47DE2BD1-87A4-401C-AC8B-336DBC678617 Q38058508-68763F17-8E8D-4C99-A337-0BD79581AC26 Q38086137-23BB1558-5B92-4A8B-90DD-B527EB032197 Q38097276-881C1831-4894-483F-A543-39C9BC9E45DD Q38104740-696D5926-4233-426E-97CC-1BC2583FE260 Q38154834-F889B62D-FDDF-45E3-85E4-E2F0629E0F98 Q38164818-6279FA4A-813C-4FF1-80EB-8463C6C98A43 Q38197519-B0CF52F8-22B2-4215-B5E9-F96726047D36 Q38241232-C0905296-64EB-461D-9F6A-CF13B2804F51 Q38288110-E448E6EB-ECF4-44CB-9F16-D2E02E3C4315 Q38507301-788A9868-2659-4E0C-98BB-420F493BA26C Q38525172-C99BA8C0-70E2-401D-B4CB-BA3B48852E82 Q38596134-E9E957EB-3344-4C64-B3AE-B13817F2CA55 Q38701990-DAD4DE7A-AAA9-43D9-82C9-A30340F168BF Q38773637-616F1986-434A-48E1-A157-A6137E310C9B Q39198220-A0B81529-FF40-4637-8DEF-FB20F4FDF334 Q39450087-2F95C882-4094-4784-9EEA-66094E260A9B Q41139937-F88F019A-BD9F-47F1-B316-4601FA16CBF1 Q42133154-0910B780-F926-47A3-AB77-415F001B9912 Q42490883-243EA8D6-5262-43A4-88B0-4A2001DA9D07 Q42638573-418F0DFA-1F3F-4FE2-B35F-119202960792 Q42698900-27DEB5AA-646B-4B4D-9DCE-9C6C0C8F9C13 Q44480906-8D577949-0567-4A85-B785-430C04E32FEE

P2860

The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.

http://www.wikidata.org/entity/Q34310749

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

The skin of patients with syst ...... receptor antibody tocilizumab.

@ast

The skin of patients with syst ...... receptor antibody tocilizumab.

@en

The skin of patients with syst ...... receptor antibody tocilizumab.

@nl

type

label

The skin of patients with syst ...... receptor antibody tocilizumab.

@ast

The skin of patients with syst ...... receptor antibody tocilizumab.

@en

The skin of patients with syst ...... receptor antibody tocilizumab.

@nl

prefLabel

The skin of patients with syst ...... receptor antibody tocilizumab.

@ast

The skin of patients with syst ...... receptor antibody tocilizumab.

@en

The skin of patients with syst ...... receptor antibody tocilizumab.

@nl

P1433

Q34310749-4D7B1CCE-208F-49BF-8A8F-E150C80ED0EA

P1476

Q34310749-1DFC1ED6-B2B8-48F7-A66C-5E7FBF818AAE

P2093

Q34310749-18CF427B-DEBF-409E-85FF-387F40556E58

Q34310749-685E9F16-EACD-47E3-888F-7C7E5F383CC1

Q34310749-831BC1FF-574F-4CA0-A5E1-E40921CE54B8

Q34310749-8E8EF0A6-6FFC-4290-A348-8F092D3324D9

Q34310749-974210A4-F073-45CA-ACC9-D06F97FB4BEE

Q34310749-A5E396E8-A2B3-49D0-8510-E3BD9FD5F56D

Q34310749-AA234F75-A86A-4BD2-99C2-B8788EC81743

Q34310749-B0683447-5A74-4AD3-BA17-F04CD7EF93D9

Q34310749-C19FA7D0-35CA-464C-984B-00F99B30582C

Q34310749-DB00E717-7294-452C-8BF6-681086FC2FA4

P2860

Q34310749-25B8CB0D-6E50-4585-AA96-E5CF4C9A0475

Q34310749-74D7BED2-9086-43B9-A07C-F21BC6FCC3E4

Q34310749-B5A17B0A-4E0E-4831-88B0-29FF7A258766

Q34310749-BA87FF36-35DB-499C-93A3-09E6E7BD879E

Q34310749-BFA9CAD4-3F86-49AB-8BCE-77B2AEFBE886

Q34310749-D4C522D7-D774-4A8D-BE57-1D43B2C106B6

Q34310749-F9FA76C6-7141-46EB-A042-5215324D15EE

P304

Q34310749-F1936F4C-04FF-4C9C-9A84-DCF93BBD96C5

P31

Q34310749-2820DD5E-2B71-4DB8-BAD1-1A79E958D570

P356

Q34310749-DCCD4658-FD30-408C-83AA-7857207A23F4

P433

Q34310749-46230D66-3BB9-4AB7-A705-1C6CF12FED1C

P478

Q34310749-8F83363D-B05E-47E2-9D05-F5C883C4300C

P50

Q34310749-E8DBC0D9-A656-421C-89C3-3DC2D7E49F44

Q34310749-E94BFBD2-C279-4D10-B269-C2329D25123E

P577

Q34310749-EE214773-AF99-4CCC-B368-F5FA6BFB84B5

P5875

Q34310749-E8A21B8F-3002-467F-8983-8061C4D8B5BB

P698

Q34310749-2054EC40-00F7-4463-BAD5-12B581223537

P921

Q34310749-157B6548-60F7-42D4-8FBB-EF0B0892FD57

Q34310749-DEBFE830-3DF8-440F-92E9-C629456A79BB

P932

Q34310749-AC2852F5-50F8-49D4-9056-84FA96A6CB36

P356

P1433

P1476

The skin of patients with syst ...... receptor antibody tocilizumab

@en

P2093

Hiroyuki Murota

http://www.w3.org/2001/XMLSchema#string

Ichiro Katayama

http://www.w3.org/2001/XMLSchema#string

Ichiro Kawase

http://www.w3.org/2001/XMLSchema#string

Junsuke Arimitsu

http://www.w3.org/2001/XMLSchema#string

Keisuke Hagihara

http://www.w3.org/2001/XMLSchema#string

Mari Kawai

http://www.w3.org/2001/XMLSchema#string

Shun Kitaba

http://www.w3.org/2001/XMLSchema#string

Tadamitsu Kishimoto

http://www.w3.org/2001/XMLSchema#string

Toru Hirano

http://www.w3.org/2001/XMLSchema#string

Toshio Tanaka

http://www.w3.org/2001/XMLSchema#string

P2860

Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis.

Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A.

Smooth muscle differentiation in scleroderma fibroblastic cells.

EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).

Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee

Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis.

Quantification of hardness, elasticity and viscosity of the skin of patients with systemic sclerosis using a novel sensing device (Vesmeter): a proposal for a new outcome measurement procedure.

P304

2408-2412

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/RHEUMATOLOGY/KEQ275

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

Masashi Narazaki

P577

2010-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46158218

http://www.w3.org/2001/XMLSchema#string

P698

20819796

http://www.w3.org/2001/XMLSchema#string

P921

P932

2981510

http://www.w3.org/2001/XMLSchema#string